The Proteasome Inhibitor, MG132, Attenuates Diabetic Nephropathy by Inhibiting SnoN Degradation In Vivo and In Vitro
Figure 2
MG132 attenuates STZ-induced downregulation of SnoN and TGF-β activation in vivo. Representative images of immunohistochemistry staining showing SnoN (a) and Smurf2 (b) expression in renal tissue. SnoN and Smurf2 expression are represented as the positive yellow-brown stained area (200x). SnoN expression in renal tissues was detected by Western blotting and RT-PCR (c): SnoN expression decreased in the DC and DT groups after injection of STZ and MG132 partially reversed SnoN degradation in the DT group; the gray graph confirmed these trends. However, the mRNA levels of SnoN were not statistically different in each group (). Morphologic parameters of kidney pathology were examined with HE ((d), 200x) and Masson staining ((e), 200x). The gray graph shows the values of semiquantitative analysis for mesangial area (Am), tuft area (At), glomerular cross-sectional area (Ag), and glomerulosclerosis index. TGF-β (f) protein expression in each group by Western blotting and the gray graph show the relative statistical values of TGF-β for each group. Data are presented as means ± SD. versus NC group; versus DC group.
